BREAKING NEWS

Spain's regulator lets PharmaMar test treatment on COVID-19 patients

By REUTERS

APRIL 29, 2021 15:26

MADRID - Spain's PharmaMar said on Thursday it received Spanish regulatory approval to carry out a late-stage trial of its Aplidin drug on patients hospitalized with moderate COVID-19 infection.

PharmaMar now has the authorization to conduct randomized controlled tests on Spanish patients to test the efficacy of its drug, usually used as a cancer treatment, in a so-called Phase III trial for use in COVID-19 cases, it said in a statement.

The company hopes to enroll a pool of 600 patients across 12 countries including France, Portugal and Sweden, as well as other countries outside Europe, the company said.

Britain's medical regulator authorized the trials two months ago after the journal Science published a paper showing the drug had encouraging antiviral results during in vitro testing.

Shares of PharmaMar were up 5.8% at 96.70 euros after it announced the regulatory decision.

Police Lahav 433 Unit investigates beginning of war incidents

By JERUSALEM POST STAFF

11/05/2024 04:38 PM

Israel strikes in Al Qusayr, Syria - report

By JERUSALEM POST STAFF

11/05/2024 04:33 PM

Trump: Kamala will start WW3, get millions of Muslims killed

By JERUSALEM POST STAFF

11/05/2024 01:10 PM

Putin tells Western diplomats Russia is committed to cooperation

By REUTERS